MCID: MNN013
MIFTS: 67

Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningitis

MalaCards integrated aliases for Meningitis:

Name: Meningitis 12 75 54 55 43 3 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9471
ICD9CM 35 322 322.9
MeSH 44 D008581
NCIt 50 C26828
SNOMED-CT 68 7180009
ICD10 33 G03 G03.8 G03.9
UMLS 72 C0025289

Summaries for Meningitis

NINDS : 54 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Meningitis is related to viral meningitis and aseptic meningitis, and has symptoms including seizures, tremor and fever. An important gene associated with Meningitis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Phenytoin and Cranberry have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology : 12 A central nervous system disease that is characterized by an inflammation of the pia-arachnoid meninges. It can be caused by growth of bacteria, fungi, or parasites within the subarachnoid space or by the growth of bacteria or viruses within the meningeal or ependymal cells.

MedlinePlus : 43 Meningitis is inflammation of the thin tissue that surrounds the brain and spinal cord, called the meninges. There are several types of meningitis. The most common is viral meningitis. You get it when a virus enters the body through the nose or mouth and travels to the brain. Bacterial meningitis is rare, but can be deadly. It usually starts with bacteria that cause a cold-like infection. It can cause stroke, hearing loss, and brain damage. It can also harm other organs. Pneumococcal infections and meningococcal infections are the most common causes of bacterial meningitis. Anyone can get meningitis, but it is more common in people with weak immune systems. Meningitis can get serious very quickly. You should get medical care right away if you have A sudden high fever A severe headache A stiff neck Nausea or vomiting Early treatment can help prevent serious problems, including death. Tests to diagnose meningitis include blood tests, imaging tests, and a spinal tap to test cerebrospinal fluid. Antibiotics can treat bacterial meningitis. Antiviral medicines may help some types of viral meningitis. Other medicines can help treat symptoms. There are vaccines to prevent some of the bacterial infections that cause meningitis. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Meningitis is an inflammation (swelling) of the protective membranes covering the brain and spinal cord. A bacterial or viral infection of the fluid surrounding the brain and spinal cord usually causes the swelling. However, injuries, cancer, certain drugs, and other types of infections also can cause meningitis. It is important to know the specific cause of meningitis because the treatment differs depending on the cause.

Wikipedia : 75 Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord,... more...

Related Diseases for Meningitis

Diseases in the Meningitis family:

Viral Meningitis Chronic Meningitis
Bacterial Meningitis

Diseases related to Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1900)
# Related Disease Score Top Affiliating Genes
1 viral meningitis 35.0 IL6 IFNG CXCL8 CRP
2 aseptic meningitis 34.7 TNF NLRP3 IL1B IL10 IFNG CXCL8
3 cryptococcal meningitis 34.7 MBL2 IFNG ADA
4 streptococcal meningitis 34.4 TNF MBL2 CRP CFP
5 tuberculous meningitis 34.4 TNF TLR2 LYZ CXCL8 ADA
6 listeriosis 33.6 TNF MBL2 IL6
7 neurosyphilis 33.5 TLR2 IL10 CXCL8
8 bacterial meningitis 33.1 TNF TLR2 PTGDS IL6 IL1B IL10
9 meningococcemia 32.9 MBL2 IL1B CFP
10 meningoencephalitis 32.7 IL6 CD40LG ALB
11 cerebral palsy 32.6 TNF MBL2 IL6 IL1B
12 mannose-binding lectin deficiency 32.6 MBL2 IL6 CFP
13 extrapulmonary tuberculosis 32.5 TLR2 IL1B IL10 IFNG ADA
14 haemophilus influenzae 32.4 TNF TLR2 IL1B CXCL8
15 neisseria meningitidis infection 32.4 TLR2 MBL2 LACTB CFP
16 leptospirosis 32.0 TNF TLR2 IL6 IL1B IL10 IFNG
17 tuberculous peritonitis 31.9 TNF IFNG CRP ALB ADA
18 miliary tuberculosis 31.9 TNF IFNG ADA
19 exanthem 31.7 TNF NLRP3 IL6 CRP
20 poliomyelitis 31.7 TNF IL10 IFNG
21 behcet syndrome 31.6 TNF MBL2 IL6 IL1B IL10 IFNG
22 uveitis 31.5 TNF IL10 IFNG
23 candidiasis 31.4 MBL2 IL10 IFNG
24 neuritis 31.4 TNF IL1B IFNG
25 purpura 31.3 TNF IL6 CRP
26 brain edema 31.3 IL6 IL1B ALB
27 septic arthritis 31.2 TLR2 CXCL8 CRP
28 pharyngitis 31.2 IL1B CXCL8 CRP
29 radiculopathy 31.2 IL6 IL10 CXCL8
30 suppurative otitis media 31.1 TLR2 IL1B CRP
31 relapsing polychondritis 31.1 IL6 IFNG CRP
32 central nervous system disease 31.1 TNF IL6 IL1B IFNG
33 infective endocarditis 31.0 TNF TLR2 IL6 CRP
34 transverse myelitis 31.0 TNF IL6 IL10 CXCL8
35 viral encephalitis 31.0 TNF IL6 IL1B IL10 CXCL8
36 mycobacterium tuberculosis 1 31.0 TNF TLR2 MBL2 IL10 IFNG ADA
37 spinal cord injury 31.0 TNF IL6 CXCL8
38 spondylitis 31.0 TNF IL6 CRP
39 respiratory failure 31.0 TNF CXCL8 CRP ALB
40 spotted fever 30.9 TNF IL10 IFNG
41 acquired immunodeficiency syndrome 30.9 TNF IL6 IL1B IL10 IFNG ALB
42 mycobacterium fortuitum 30.9 LACTB CXCL8
43 salmonellosis 30.9 LACTB IL1B IFNG ALB
44 osteomyelitis 30.9 TNF IL6 IL1B IL10 IFNG CXCL8
45 mixed connective tissue disease 30.9 TNF IL6 IL10 IFNG
46 conjunctivitis 30.9 NLRP3 IL6 IFNG CXCL8
47 pertussis 30.9 TNF IL6 IL1B IL10
48 rubella 30.9 TNF IL10 CD40LG
49 myocarditis 30.9 TNF IL6 CD40LG
50 lymphadenitis 30.9 TNF IL1B IL10 IFNG CXCL8

Comorbidity relations with Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Meningitis
Deficiency Anemia Hypertension, Essential

Graphical network of the top 20 diseases related to Meningitis:



Diseases related to Meningitis

Symptoms & Phenotypes for Meningitis

UMLS symptoms related to Meningitis:


seizures, tremor, fever, pruritus, back pain, pain, headache, hemiplegia, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, meningism, hyperexplexia

MGI Mouse Phenotypes related to Meningitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ADA ALB CD40LG CFP CRP IFNG
2 immune system MP:0005387 10.28 ADA CD40LG CFP CRP IFNG IL10
3 hematopoietic system MP:0005397 10.27 ADA CD40LG IFNG IL10 IL1B IL6
4 cardiovascular system MP:0005385 10.26 ADA CD40LG CFP CRP IFNG IL10
5 cellular MP:0005384 10.25 ADA ALB CD40LG IFNG IL10 IL6
6 endocrine/exocrine gland MP:0005379 10.18 ADA ALB CD40LG IFNG IL10 IL6
7 digestive/alimentary MP:0005381 10.15 ADA ALB IFNG IL10 IL6 LYZ
8 integument MP:0010771 10.07 CD40LG IFNG IL10 IL1B IL6 LYZ
9 mortality/aging MP:0010768 10.07 ADA ALB CD40LG CFP IFNG IL10
10 liver/biliary system MP:0005370 9.97 ADA ALB IFNG IL10 IL6 LYZ
11 neoplasm MP:0002006 9.81 ALB IFNG IL10 IL1B IL6 LYZ
12 renal/urinary system MP:0005367 9.61 ADA ALB CD40LG IFNG IL6 LYZ
13 skeleton MP:0005390 9.4 ADA CD40LG CFP IFNG IL10 IL1B

Drugs & Therapeutics for Meningitis

Drugs for Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
2 Cranberry Approved, Investigational Phase 4
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
6
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
7
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
8
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
9
Cefoxitin Approved Phase 4 35607-66-0 441199
10
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
15
Ziconotide Approved Phase 4 107452-89-1 447451
16
Cosyntropin Approved Phase 4 16960-16-0 16129617
17
Azathioprine Approved Phase 4 446-86-6 2265
18
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
20
Sodium citrate Approved, Investigational Phase 4 68-04-2
21
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
22
Azithromycin Approved Phase 4 83905-01-5 447043 55185
23
leucovorin Approved Phase 4 58-05-9 143 6006
24
Sulfamethoxazole Approved Phase 4 723-46-6 5329
25
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
26
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
27
Zidovudine Approved Phase 4 30516-87-1 35370
28
Nevirapine Approved Phase 4 129618-40-2 4463
29
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
30
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
33
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
36 Cyclosporins Phase 4
37 Complement Factor H Phase 4
38 Hormones Phase 4
39 Hormone Antagonists Phase 4
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
41 Liposomal amphotericin B Phase 4
42 Antiemetics Phase 4
43 Anti-Inflammatory Agents Phase 4
44 HIV Protease Inhibitors Phase 4
45 glucocorticoids Phase 4
46
protease inhibitors Phase 4
47 Antineoplastic Agents, Hormonal Phase 4
48 Autonomic Agents Phase 4
49 BB 1101 Phase 4
50 Heptavalent Pneumococcal Conjugate Vaccine Phase 4

Interventional clinical trials:

(show top 50) (show all 611)
# Name Status NCT ID Phase Drugs
1 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
2 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
3 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
4 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
5 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
6 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
7 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Unknown status NCT02569632 Phase 4
8 A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
9 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
10 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
11 Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. Completed NCT01745679 Phase 4 Ceftriaxone treatment
12 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
13 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
14 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
15 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
16 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola. Completed NCT01540838 Phase 4 Infusion with paracetamol;Bolus without paracetamol
17 An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi Completed NCT01247909 Phase 4 Ceftriaxone v penicillin and gentamicin
18 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
19 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
20 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
21 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
22 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
23 Determination of Gentamicin Dosing in Neonatal Patients for Use in the Uniject Pre-filled Syringe [A Three-site Study at: 1) Dhaka Shishu Hospital, Dhaka Bangladesh; 2) Christain Medical Center, Vellore, India; and 3) Aga Khan University Medical Center, Karachi, Pakistan] Completed NCT00198601 Phase 4 Gentamicin in Uniject Pre-filled syringe
24 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
25 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
26 Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China Completed NCT01430611 Phase 4
27 Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135 Completed NCT00850603 Phase 4
28 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
29 The Impact of Vaccination With a Serogroup A Meningococcal Conjugate Vaccine on Carriage of Serogroup A Meningococci in Mali and Niger Completed NCT01119482 Phase 4
30 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
31 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
32 A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants Completed NCT00581035 Phase 4
33 A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine Completed NCT01823536 Phase 4
34 Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants Completed NCT02040402 Phase 4
35 Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis Completed NCT00119080 Phase 4
36 A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB) Completed NCT02080559 Phase 4
37 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
38 Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients Completed NCT01781871 Phase 4
39 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
40 Open Label Study of Lung and Serum Immunoglobulin Responses to 7-Valent Pneumococcal Conjugate Vaccine in HIV Infected and Non-HIV Infected Malawian Adults Completed NCT00371878 Phase 4
41 Evaluation of Meropenem Penetration Across Blood-Brain Barrier in Patients With Central Nervous System Infection After Neurosurgery and Optimization of Meropenem Treatment Completed NCT02506686 Phase 4 Meropenem
42 A Phase 4, Randomized, Single-blind Trial to Evaluate Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine When Administered Simultaneously With Trivalent Inactivated Influenza Vaccine in Healthy Children Aged 3-7years and Healthy Adults 65 Aged 50-65years. Completed NCT02062281 Phase 4
43 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
44 An Open Label Single-arm Trial of the Immunogenicity and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine (Prevenar13®) Given to Children With Type 1 Diabetes Mellitus Who Have Not Previously Received a Primary Schedule of Immunisation With Pneumococcal Conjugate Vaccines in Infancy. Completed NCT01939522 Phase 4
45 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza the in São Paulo, 2009 Completed NCT01693380 Phase 4
46 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
47 A Pilot Study of the Impact of BCG Administration on the Immunogenicity of Serogroup C Meningococcal Conjugate Vaccine in Healthy Infants Completed NCT02002156 Phase 4
48 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
49 Evaluation of Meningococcal C Vaccine Programmes in Canadian (BC, NS, Alta.) Children During Peak Years of Risk (0-<5 Years of Age) Completed NCT00936962 Phase 4
50 Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache (PDPH) Completed NCT02394457 Phase 4 Cosyntropin

Search NIH Clinical Center for Meningitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Benzylpenicillin
Cefuroxime
Metronidazole

Cochrane evidence based reviews: meningitis

Genetic Tests for Meningitis

Anatomical Context for Meningitis

MalaCards organs/tissues related to Meningitis:

41
Brain, Testes, Spinal Cord, Pituitary, Lung, Breast, Bone

Publications for Meningitis

Articles related to Meningitis:

(show top 50) (show all 30037)
# Title Authors PMID Year
1
Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study. 38 17
31242860 2019
2
Pediatric glial fibrillary acidic protein meningoencephalomyelitis: A case report and review of the literature. 17
30885369 2019
3
Fungal diseases at the medical front door. 17
30860923 2019
4
Comparative analysis of cerebrospinal fluid adenosine deaminase in tuberculous and non-tuberculous meningitis. 9 38
20399005 2010
5
Adenosine deaminase and tuberculous meningitis--a systematic review with meta-analysis. 9 38
20001225 2010
6
HLA-DRB1*01 allele and low plasma immunoglobulin G1 concentration may predispose to herpes-associated recurrent lymphocytic meningitis. 9 38
19879913 2010
7
Very late-onset group B Streptococcus meningitis, sepsis, and systemic shigellosis due to interleukin-1 receptor-associated kinase-4 deficiency. 9 38
19814626 2009
8
[A case of listeria meningitis showed high levels of adenosine deaminase in cerebrospinal fluid]. 9 38
19928691 2009
9
Bacterial meningitis: rapid diagnosis and microbial profile: a multicentered study. 9 38
19301695 2008
10
C-reactive protein as an indicator of aqueductal gliosis and hydrocephaly in neonatal meningitis. 9 38
18581011 2008
11
Comparative study of cerebrospinal fluid adenosine deaminase activity in patients with meningitis. 9 38
17899959 2007
12
A case of Listeria meningitis associated with increased adenosine deaminase in cerebrospinal fluid. 9 38
17141462 2007
13
Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. 9 38
16920154 2006
14
Serum concentrations of interleukin-1 alpha, interleukin-6 and tumor necrosis factor-alpha in neonatal sepsis and meningitis. 9 38
17013473 2006
15
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 9 38
17333738 2006
16
Expression of innate immune complement regulators on brain epithelial cells during human bacterial meningitis. 9 38
16948860 2006
17
Interleukin-1alpha, interleukin-6 and tumor necrosis factor-alpha levels in children with sepsis and meningitis. 9 38
16635168 2006
18
[Lymphocytis meningitis: Listeria monocytogenes is a potential risk in a immunocompetent child]. 9 38
16185855 2005
19
Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. 9 38
15825022 2005
20
Elevated serum C-reactive protein in mumps orchitis. 9 38
15602206 2004
21
Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. 9 38
15105095 2004
22
[Concentration of proinflammatory cytokines (TNF-alpha, IL-8) in the cerebrospinal fluid and the course of bacterial meningitis]. 9 38
15230146 2004
23
Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. 9 38
12952922 2003
24
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. 9 38
12480084 2003
25
Neurotrophin-4 and glial cell line-derived neurotrophic factor in cerebrospinal fluid from meningitis/encephalitis patients. 9 38
12213609 2002
26
Interleukin-8 levels in children with bacterial, tuberculous and aseptic meningitis. 9 38
12003295 2002
27
Worldwide variation in the incidence of Haemophilus influenzae type b meningitis and its association with ampicillin resistance. 9 38
11939404 2002
28
[Does the estimation of acute phase protein concentrations in cerebrospinal fluid and/or in serum in patients with viral meningitis carry diagnostic importance? Part I. Lymphocytic meningitis caused by epidemic parotitis]. 9 38
12666587 2002
29
The possible role of cerebrospinal fluid adenosine deaminase activity in the diagnosis of tuberculous meningitis in adults. 9 38
11792470 2002
30
[Clinical study of 33 children with systemic pneumococcal infections]. 9 38
11806134 2001
31
Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. 9 38
11709004 2001
32
[Chemokines in meningitis of different etiologies]. 9 38
11320578 2001
33
Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. 9 38
11763415 2001
34
Follistatin (FS) in human cerebrospinal fluid and regulation of FS expression in a mouse model of meningitis. 9 38
11124865 2000
35
Adenosine deaminase levels in cerebrospinal fluid and serum in the diagnosis of tubercular meningitis. 9 38
11191154 2000
36
Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. 9 38
10992482 2000
37
Serum C-reactive protein in the differential diagnosis of childhood meningitis. 9 38
11059546 2000
38
[Serial measurement of anti-interleukin-8 IgG autoantibody in cerebrospinal fluid of infants with bacterial meningitis]. 9 38
11109762 2000
39
Association of familial deficiency of mannose-binding lectin and meningococcal disease. 9 38
10509505 1999
40
Fc gamma receptor allotypes in children with bacterial meningitis. A preliminary study. 9 38
10028861 1998
41
[Quantitative levels of serum amyloid A protein and other proteins in cerebrospinal fluid and serum of patients with meningitis]. 9 38
9800479 1998
42
The production of macrophage inflammatory protein-1alpha in the cerebrospinal fluid at the initial stage of meningitis in children. 9 38
9396559 1997
43
Levels of interleukin-6, CRP and alpha 2 macroglobulin in cerebrospinal fluid (CSF) and serum as indicator of blood-CSF barrier damage. 9 38
9350334 1997
44
[Bacterial meningitis and CSF cytokines]. 9 38
15034315 1997
45
[Evaluation of tumor necrosis factor and C-reactive protein level determination in cerebrospinal fluid of meningitis and encephalitis]. 9 38
9424322 1997
46
[Detection of Neisseria meningitidis group B antigens by MB-Dot-Elisa test in patients with meningitis]. 9 38
9162589 1997
47
[Nitric oxide, TNF-alpha and IL-8 in cerebrospinal fluids of tuberculous and cryptococcic meningitis]. 9 38
10072993 1997
48
Detection of N. meningitidis group B antigens by MB-Dot-ELISA in patients with meningitis. 9 38
8897721 1996
49
Chemokines in the cerebrospinal fluid of patients with meningitis. 9 38
8764560 1996
50
Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. 9 38
8801091 1996

Variations for Meningitis

Expression for Meningitis

Search GEO for disease gene expression data for Meningitis.

Pathways for Meningitis

Pathways related to Meningitis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF TLR2 NLRP3 MBL2 LYZ IRAK4
2
Show member pathways
13.73 TNF IL6 IL1B IL10 IFNG CXCL8
3
Show member pathways
13.51 TNF TLR2 IRAK4 IL6 IL1B IL10
4
Show member pathways
13.45 TNF IRAK4 IL6 IL1B IL10 IFNG
5
Show member pathways
13.39 TNF IL6 IL1B IL10 CXCL8 CXCL1
6
Show member pathways
13.08 TNF TLR2 IRAK4 IL6 IL1B CXCL8
7
Show member pathways
12.99 TNF IL6 IL1B IL10 IFNG CXCL8
8
Show member pathways
12.97 TNF TLR2 NLRP3 MBL2 IRAK4 IL6
9
Show member pathways
12.86 TNF IL6 IL1B IFNG CXCL8 CCL4
10
Show member pathways
12.81 TNF TLR2 IRAK4 IL6 IL1B CD40LG
11
Show member pathways
12.71 TNF TLR2 IL6 IL1B IL10 IFNG
12
Show member pathways
12.7 TNF IL6 IL1B IL10 IFNG CXCL1
13
Show member pathways
12.69 TNF IL6 IL1B IL10 IFNG CD40LG
14 12.68 TNF TLR2 IRAK4 IL1B IL10 IFNG
15
Show member pathways
12.66 TNF TLR2 IRAK4 IL1B CD40LG
16
Show member pathways
12.46 TNF IL6 IL1B IFNG CRP ALB
17
Show member pathways
12.45 TNF TLR2 IL6 IL1B IFNG CXCL8
18
Show member pathways
12.44 TNF IRAK4 IL6 IL1B IFNG CXCL8
19
Show member pathways
12.38 TNF TLR2 IRAK4 IL6 CXCL8
20
Show member pathways
12.38 TNF IL6 IL1B IL10 IFNG CXCL8
21
Show member pathways
12.38 TNF TLR2 IRAK4 IL1B IL10 IFNG
22
Show member pathways
12.35 TNF TLR2 IRAK4 IL6 IL1B CXCL8
23
Show member pathways
12.33 TNF NLRP3 IL6 IL1B IL10
24 12.33 TNF TLR2 IRAK4 IL6 IL1B IL10
25
Show member pathways
12.31 TLR2 IRAK4 IL1B CXCL8 CXCL1 CCL4
26 12.29 TNF IL6 IL1B IL10 CXCL8
27
Show member pathways
12.27 TNF NLRP3 IL1B IFNG
28
Show member pathways
12.27 TNF TLR2 IRAK4 IL6 IL1B IFNG
29 12.25 TNF TLR2 IL6 IFNG
30
Show member pathways
12.19 IL6 IL1B IL10 IFNG CXCL8 CCL4
31
Show member pathways
12.19 TNF TLR2 IL6 IL1B IL10 IFNG
32
Show member pathways
12.17 TNF TLR2 IL6 IL1B IFNG
33 12.15 TNF IL6 IL1B IFNG CXCL8 CXCL1
34 12.12 TNF IL6 IL1B IL10 CXCL8
35 12.09 TNF IL6 IL10 IFNG
36 12.08 IL6 IL1B IFNG CXCL8 CXCL1
37 12.07 TNF IL6 IL1B CXCL1
38 12.05 TNF IRAK4 IL1B CXCL8 CD40LG CCL4
39 12.01 TNF IL6 IL1B CXCL8
40 11.95 TNF TLR2 IL6 IL1B IFNG CXCL8
41 11.91 TNF IL1B IL10 IFNG
42 11.91 IL6 IL1B IFNG CXCL8 CXCL1 CCL4
43
Show member pathways
11.89 TNF IFNG CXCL8 CD40LG
44 11.88 TNF IL6 IL1B IL10 IFNG
45 11.83 IL6 IFNG CXCL8
46 11.83 TNF NLRP3 IRAK4 IL6 IL1B IL10
47 11.8 TNF IL6 IL1B CXCL8 CCL4
48
Show member pathways
11.77 TNF IL6 IL1B IFNG CXCL8 CD40LG
49 11.76 TNF IL6 IL1B IL10 IFNG CXCL1
50 11.7 TNF TLR2 IL6 IL1B CXCL8 CXCL1

GO Terms for Meningitis

Cellular components related to Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF PTGDS NLRP3 MBL2 LYZ IL6
2 extracellular space GO:0005615 9.55 TNF PTGDS MBL2 LYZ IRAK4 IL6
3 specific granule lumen GO:0035580 9.43 LYZ CXCL1 CFP
4 tertiary granule lumen GO:1904724 9.33 LYZ CXCL1 CFP

Biological processes related to Meningitis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.97 TNF NLRP3 CXCL8 CXCL1
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL1B IL10
3 cytokine-mediated signaling pathway GO:0019221 9.92 TNF IRAK4 IL6 IL1B IL10 CXCL8
4 cellular response to lipopolysaccharide GO:0071222 9.91 TNF NLRP3 IL6 IL1B IL10 CXCL8
5 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CXCL1 CCL4
6 regulation of insulin secretion GO:0050796 9.89 TNF IL1B IFNG
7 positive regulation of T cell proliferation GO:0042102 9.88 IL6 IL1B CD40LG
8 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
9 neutrophil chemotaxis GO:0030593 9.88 IL1B CXCL8 CXCL1 CCL4
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF IRAK4 IL6
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF TLR2 IL1B
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG
13 positive regulation of phagocytosis GO:0050766 9.84 TNF MBL2 IL1B
14 acute-phase response GO:0006953 9.83 MBL2 IL6 CRP
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR2 IL1B
16 positive regulation of interleukin-8 production GO:0032757 9.81 TNF TLR2 IL1B
17 positive regulation of interleukin-6 production GO:0032755 9.8 TNF TLR2 IL6 IL1B
18 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF TLR2 NLRP3 IRAK4 IL6 IL1B
19 positive regulation of interleukin-12 production GO:0032735 9.79 TLR2 IFNG CD40LG
20 negative regulation of neurogenesis GO:0050768 9.79 TNF IL6 IL1B
21 leukocyte chemotaxis GO:0030595 9.78 IL10 CXCL8 CXCL1
22 positive regulation of chemokine production GO:0032722 9.75 TNF TLR2 IL6
23 embryonic digestive tract development GO:0048566 9.74 TNF CXCL8 ADA
24 positive regulation of glial cell proliferation GO:0060252 9.73 TNF IL6 IL1B
25 opsonization GO:0008228 9.72 MBL2 CRP
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF IL1B IFNG
27 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TNF IL1B
28 neutrophil mediated immunity GO:0002446 9.71 IRAK4 IL6
29 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
30 response to glucocorticoid GO:0051384 9.71 TNF IL6 IL10
31 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
32 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.7 PTGDS ADA
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 TNF IL1B IL10
34 defense response to Gram-positive bacterium GO:0050830 9.7 TNF TLR2 NLRP3 MBL2 LYZ IL6
35 immune response GO:0006955 9.7 TNF TLR2 IL6 IL1B IL10 IFNG
36 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.69 NLRP3 IL6
37 negative regulation of cytokine secretion involved in immune response GO:0002740 9.69 TNF IL10
38 negative regulation of growth of symbiont in host GO:0044130 9.69 TNF MBL2 IL10
39 regulation of immunoglobulin secretion GO:0051023 9.68 TNF CD40LG
40 positive regulation of fever generation GO:0031622 9.68 TNF IL1B
41 interleukin-1 beta production GO:0032611 9.68 NLRP3 IL1B
42 sequestering of triglyceride GO:0030730 9.67 TNF IL1B
43 receptor biosynthetic process GO:0032800 9.65 TNF IL10
44 cytokine secretion involved in immune response GO:0002374 9.65 TLR2 NLRP3
45 response to molecule of bacterial origin GO:0002237 9.65 TLR2 IL10 CXCL8
46 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
47 positive regulation of vitamin D biosynthetic process GO:0060557 9.62 TNF IFNG
48 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6 IL1B
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IL1B IFNG
50 inflammatory response GO:0006954 9.4 TNF TLR2 NLRP3 LYZ IL6 IL1B

Molecular functions related to Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TNF TLR2 NLRP3 LYZ LACTB CRP
2 chemokine activity GO:0008009 9.33 CXCL8 CXCL1 CCL4
3 cytokine activity GO:0005125 9.28 TNF IL6 IL1B IL10 IFNG CXCL8
4 protein binding GO:0005515 10.19 TNF TLR2 PTGDS NLRP3 MBL2 IRAK4

Sources for Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....